Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 29, 2026
TickeronGET DAILY SIGNALS
Why Is ClearPoint Neuro (CLPT) Stock Down -21.62% Today?

Why Is ClearPoint Neuro (CLPT) Stock Down -21.62% Today?

Key Takeaways

  • CLPT shares fell approximately 21.62% on Tuesday, sliding from a prior close of $15.31 to about $12.00.
  • The sell-off was triggered by disappointing 48-month clinical data from gene therapy partner uniQure, whose Huntington's disease candidate missed statistical significance on a key endpoint.
  • ClearPoint Neuro supplies the MRI-guided navigation platform and SmartFlow cannula used to deliver uniQure's AMT-130 therapy, making the stock highly sensitive to its partner's trial outcomes.
  • The move rippled through the broader cell and gene therapy tools complex, though ClearPoint's drop was amplified by its concentrated exposure to the AMT-130 program.
  • Traders are now watching uniQure's regulatory path and ClearPoint's upcoming quarterly results for signals on the durability of its drug delivery revenue pipeline.

Opening Summary

ClearPoint Neuro, Inc. (CLPT), a developer of MRI-guided navigation, drug delivery, and neurosurgical technologies used in cell and gene therapy procedures, saw its stock plunge sharply on Tuesday. The shares fell roughly 21.62%, dropping from a prior session close of $15.31 to approximately $12.00 in intraday trading. The decline came after partner uniQure N.V. (QURE) reported four-year data for its investigational Huntington's disease gene therapy, ifezuntirgene inilparvovec (AMT-130), which missed statistical significance on a primary clinical measure. Because ClearPoint's SmartFlow cannula and ClearPoint navigation system are used to deliver AMT-130 directly into the brain, investors reassessed the company's future commercial revenue tied to the program, triggering the sharp sell-off.

Catalyst Breakdown: uniQure's Disappointing 48-Month Data

The primary driver of the decline was sector sympathy with uniQure, whose U.S.-listed shares cratered more than 55% in premarket trading. uniQure's 48-month analysis showed that high-dose patients experienced a 44% slowing of disease progression on the composite Unified Huntington's Disease Rating Scale (cUHDRS), but the result carried a p-value of 0.144, falling short of statistical significance.

The market reaction matters for CLPT because ClearPoint's technology is embedded in the AMT-130 delivery process. The therapy is administered through targeted, MRI-guided, convection-enhanced neurosurgical delivery using ClearPoint's navigation platform and SmartFlow cannula. Any setback that clouds AMT-130's regulatory or commercial outlook directly reduces the potential demand for ClearPoint's disposable cannulas and clinical support services.

uniQure attributed the statistical miss to "survivor bias" in its updated external control dataset, noting that 53% of control patients had dropped out by month 48, leaving a healthier comparator group. A post-hoc analysis using an earlier control dataset restored statistical significance (54% slowing, p=0.041), but investors typically discount after-the-fact statistical adjustments. Importantly, the FDA previously agreed that 36-month data — which showed an 80% slowing on cUHDRS (p=0.005) and a 67% slowing on Total Functional Capacity (p=0.011) — would serve as the primary basis for uniQure's already-submitted Biologics License Application under the accelerated approval pathway. Still, the weaker durability signal rattled confidence in the program's long-term commercial ramp.

Market Context and Trading Activity

The decline in CLPT unfolded as a partner-driven, event-specific move rather than a broad-market pullback. ClearPoint's exposure is concentrated: AMT-130 has been among its most visible and highest-value drug delivery collaborations, with modeled per-patient revenue estimates in the roughly $15,000 to $25,000 range for uniQure procedures. The sharp drop in QURE shares — down more than half — dragged sentiment across the cell and gene therapy delivery niche, with ClearPoint trading down in sympathy.

Volume was heavy relative to recent sessions, consistent with institutional repositioning following the data readout. The stock had recently recovered from a period of pressure tied to second-quarter results and a 2026 revenue guidance cut, making Tuesday's move a sharp reversal that pushed the shares well below their recent trading range. The price action reflects a market repricing of the probability that ClearPoint's drug delivery franchise accelerates as quickly as bulls had hoped.

What Comes Next for CLPT

Looking ahead, investors will focus on several factors. The first is uniQure's regulatory trajectory: while the 36-month data underpins its BLA, any additional regulatory feedback could reverberate through CLPT. ClearPoint's own fundamentals also matter — the company recently lowered its 2026 revenue guidance to $48–$52 million and flagged an investment-heavy year as it builds out its ClearPoint Advanced Laboratories facility and expands its clinical specialist team. Its next quarterly earnings report is expected around early November, offering a checkpoint on cash burn, biologics and drug delivery revenue, and the progress of its broader 60-plus partner base.

Risks remain balanced. The company's diversification across numerous cell and gene therapy collaborations provides some insulation from any single program, but the market has demonstrated that headline partner setbacks can still dominate near-term trading. Cash runway, dilution risk, and execution on preclinical and GLP services will all be watched closely.

Trending AI Robots

For traders seeking a data-driven edge in volatile markets, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the most robust results under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches aligned with their own objectives. Consider exploring the Trending AI Robots to see which automated strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLPT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CLPT sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for CLPT moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 84 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 49 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

CLPT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CLPT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 217 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (24.345) is slightly higher than the industry average of (4.142). P/E Ratio (-7.288) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.

Industry MedicalNursingServices

Industry
N/A
Address
120 S. Sierra Avenue
Phone
+1 888 287-9109
Employees
172
Web
https://www.clearpointneuro.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.